Study of REGEND003 for type 2 diabetes with kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment, REGEND003, for people who have both type 2 diabetes and chronic kidney disease. The goal is to see if it can help manage these conditions together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 75 years old.
- You have had type 2 diabetes for at least 1 year.
- You have chronic kidney disease (CKD).
- You are not on regular dialysis or have had a kidney transplant.
- You do not have type 1 diabetes or a history of certain infections or cancers.
- You can keep a diary and follow study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This study looks at how different levels of kidney function affect the amount of a medication in the body. It may help doctors decide on the right dose for people with kidney problems.
This study tests a new drug called IGT-303 for people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and can help protect kidney function.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This trial tests a new system to manage diabetic kidney disease across all stages. It is for people with type 2 diabetes who either have no kidney damage or have kidney damage confirmed by a biopsy.
This early-stage trial tests a new drug called ONO-3310 in two groups: healthy adults and people with kidney disease caused by type 2 diabetes. The study aims to understand how the drug works and whether it might help protect kidney function in people with diabetes.
Hear when a new Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.